Table 1.
Comparison of State-of-the-Art Organoid Centers
| TMDU | The HUB | INTENS | YCU | CuSTOM | |
|---|---|---|---|---|---|
| Mission | Organoid tx | Organoid biobank | Organoid tx | Organoid tx | Organoid medicine |
| Organ | Intestine | Multiple | Intestine | Liver | Multiple |
| Indication | Inflammatory bowel disease | NA | Short gut syndrome | Metabolic liver disease | NA |
| Country | Japan | EU | EU | Japan | US |
| Stem Cell Source | ASC | ASC | ASC | PSC | PSC/ ASC |
| Funding source | AMED | ND | Horizon2020 | AMED | CCHMC/ Philanthropy |
| First in Human | 2018- | ND | ND | 2020- | ND |
| Core facility | − | ND | ND | − | + |
| Industry partners | + | ND | + | + | + |
| Accelerator infrastructure | − | − | − | − | + |
| cGMP facility | + | ND | ND | + | + |